Codexis (CDXS) Insider Stewart Parker Buys 66,350 Shares
A group of insiders added to their stakes in Codexis, Inc. on June 17, 2026, acquiring 66,350 shares each.
Reviewed by automated data checks against the source filing. How we make and check alerts
Stewart Parker bought 66,350 shares of Codexis, Inc. ($CDXS) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CDXS is down 8.5% after 1 week, down 9.7% after 1 month and down 50.0% to date (from the $2.48 close on Jun 17, 2026).
CDXS
Codexis, Inc.
Key Points
- Stewart Parker and several other insiders each acquired 66,350 shares of Codexis, Inc. on June 17, 2026.
- Codexis stock trades near $2.57, well above its 52-week low of $0.96 and approaching its high of $2.98.
- Piper Sandler maintained an Overweight rating on Codexis with an adjusted price target of $8.00 on August 17, 2026.
Get $CDXS trade alerts by text
We text you when insiders, Congress or big funds trade $CDXS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Codexis, Inc. alert may contain errors. Disclosures
Multiple Insiders Add to Stakes at Codexis
Stewart Parker joined a group of company insiders in picking up shares of Codexis, Inc. (NasdaqGS: CDXS) on June 17, 2026. The transaction involved acquiring 66,350 shares of the biotechnology firm. This group purchase highlights a coordinated round of insider acquisitions taking place on the exact same date for multiple figures connected to the business.
A Shared Buying Pattern Across the Board
The cluster of transactions on June 17, 2026, brought identical share blocks of 66,350 shares to several individuals. De Vre Raymond, Cynthia Collins, Dilly Stephen George, Esther Martinborough, Rahul Singhvi, and David Smith each added 66,350 shares to their respective holdings on that day. These concurrent transactions underscore a notable wave of insider activity for the Redwood City, California-based firm.
Codexis Stock Moves Higher in 2026
Shares of Codexis trade at $2.57, reflecting a recovery from earlier lows and sitting closer to the top of its yearly trading range. The equity has moved between a 52-week low of $0.96 and a 52-week high of $2.98. With a market value of roughly $151.1 million, the biotechnology company has captured attention as its share price climbs above its 50-day moving average of $1.62 and its 200-day moving average of $1.87.
Piper Sandler Adjusts Outlook on the Stock
Analyst coverage from Piper Sandler provides additional context on how Wall Street views the company's trajectory. On August 17, 2026, Piper Sandler maintained its Overweight rating on Codexis while adjusting its price target from $9.00 to $8.00. Across the broader analyst community, the stock holds a consensus Buy rating based on seven analyst opinions, with a mean price target of $6.14.
Inside the Biotechnology Business
Codexis, Inc. develops technology solutions for therapeutics manufacturing, utilizing its proprietary CodeEvolver technology platform to discover and enhance novel enzymes. The company also builds the ECO Synthesis manufacturing platform for scaled production of RNAi therapeutics through enzymatic routes. Based in Redwood City, California, and founded in 2002, the firm employs 146 people and works alongside partners like Pfizer and Aldevron.
Looking Ahead to Upcoming Filings
Investors tracking Codexis will likely watch for the company's next financial update scheduled for November 5, 2026, to gauge operational progress. As always, insider transactions offer a look at how leaders manage their personal holdings but do not replace a complete review of company fundamentals and broader market conditions.
Related Filing Alerts
Source: Stewart Parker's Form 4 filing on $CDXS (Jun 17, 2026). Find the original filing: CDXS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts